PMN310 has been granted Fast Track Designation by the U.S. FDA for the treatment of Alzheimer’s disease.

View Press Release

Innovative Protein Folding Predictions

A Revolutionary Breakthrough in Precision Medicine

Based on the leading science of Dr. Neil Cashman, our proprietary target discovery engine, EpiSelect™, utilizes computational discovery technologies to predict and identify toxic misfolded proteins implicated in the development and progression of neurodegenerative and other misfolded protein diseases.

About Our Science

A Growing Portfolio of Selective Antibody Therapeutic Product Candidates

Our portfolio leverages a revolutionary approach that enables the tailoring of therapeutic antibodies with a high degree of selectivity for the key drivers of multiple neurodegenerative and other misfolded protein diseases, including:

  • Alzheimer’s disease (AD)
  • Amyotrophic lateral sclerosis (ALS)
  • Frontotemporal dementia (FTD)
  • Multiple System Atrophy (MSA)
  • Parkinson’s disease (PD)
View Product Pipeline

Addressing Neurodegenerative and Other Misfolded Protein Diseases Using Novel Biologic Products

We are ProMIS Neurosciences, a leading clinical-stage biotechnology company based in Toronto, Ontario and Cambridge, Massachusetts. Our large team of multidisciplinary experts is committed to the discovery and development of selective antibody therapies that combat neurodegenerative and other misfolded protein diseases at the source.

About Our Company

Latest News

View All News

ProMIS Neurosciences Announces Private Placement Financing

ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease

View All News

Stock Snapshot